| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEC2 |
| Uniprot No | Q9UBF1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-373aa |
| 氨基酸序列 | MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSSLILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQKGEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPVILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIKGNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFLWGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASESLSVMSSNVSFSE |
| 预测分子量 | 46.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAGEC2重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*MAGEC2 promotes tumor progression through regulating cell proliferation and immune evasion in melanoma*
**作者**：Smith A, et al.
**摘要**：本研究利用重组MAGEC2蛋白，揭示了其在黑色素瘤细胞中的促增殖作用，并证明其通过抑制MHC-I分子表达帮助肿瘤逃避免疫监视。重组蛋白的体外实验表明，MAGEC2与E3泛素连接酶复合体相互作用，调控下游信号通路。
2. **文献名称**：*Structural and functional characterization of recombinant MAGEC2 reveals its role in DNA repair*
**作者**：Zhang Y, et al.
**摘要**：通过大肠杆菌系统成功表达并纯化重组MAGEC2蛋白，晶体结构分析显示其含有保守的MAGE homology domain。功能实验表明，MAGEC2与RING1蛋白结合，增强同源重组修复能力，可能解释其在肿瘤基因组不稳定性中的作用。
3. **文献名称**：*MAGEC2-derived epitopes identified by recombinant protein screening induce cytotoxic T-cell responses in ovarian cancer*
**作者**：Lee HJ, et al.
**摘要**：利用重组MAGEC2蛋白筛选HLA-A2限制性表位，发现多个可被CD8+ T细胞识别的抗原肽。体外实验证实这些表位能激活患者T细胞，杀伤MAGEC2阳性卵巢癌细胞，提示其作为免疫治疗靶点的潜力。
注：以上文献为示例性概括，实际引用时需以真实发表的论文为准。
MAGEC2 (melanoma-associated antigen C2) is a member of the MAGE family of cancer/testis antigens (CTAs), which are characterized by their restricted expression in normal tissues (primarily in germ cells) and aberrant reactivation in various cancers. Encoded by the *MAGEC2* gene located on the X chromosome, this protein shares homology with other MAGE family members, featuring a conserved MAGE homology domain involved in protein-protein interactions. Its expression is epigenetically silenced in most somatic cells but re-emerges in malignancies such as melanoma, lung, liver, and ovarian cancers, making it a potential target for immunotherapy.
Recombinant MAGEC2 protein is produced using expression systems like *E. coli* or mammalian cells, followed by purification via affinity chromatography. It serves as a critical tool for studying MAGEC2's biological roles, including its interaction with E3 ubiquitin ligases (e.g., TRIM28) to modulate ubiquitination pathways, and its proposed involvement in promoting tumor cell survival, metastasis, and resistance to apoptosis. Research also explores its role in epigenetic regulation, possibly influencing oncogenic transcription factors.
Clinically, recombinant MAGEC2 is investigated for diagnostic and therapeutic applications. Its cancer-specific expression profile positions it as a biomarker for liquid biopsies or imaging probes. In immunotherapy, it acts as an antigen for vaccines or engineered T-cell therapies (e.g., CAR-T), aiming to enhance immune recognition of MAGEC2-positive tumors. However, challenges persist, including tumor heterogeneity, low immunogenicity, and potential off-target effects due to shared epitopes with other MAGE proteins.
Current studies leverage CRISPR-Cas9 screening and omics technologies to unravel MAGEC2's context-dependent functions and optimize therapeutic strategies. Despite its promise, further validation of safety and efficacy in preclinical models is essential before clinical translation.
×
